Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area

MeSH terms

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents / administration & dosage*
• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / pharmacokinetics
• Antineoplastic Agents / therapeutic use
• Asian People / statistics & numerical data
• Benzamides
• Body Surface Area*
• Dose-Response Relationship, Drug
• Edema / chemically induced
• Female
• Humans
• Imatinib Mesylate
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / ethnology
• Male
• Middle Aged
• Neutropenia / chemically induced
• Piperazines / administration & dosage*
• Piperazines / adverse effects
• Piperazines / pharmacokinetics
• Piperazines / therapeutic use
• Protein Kinase Inhibitors / administration & dosage*
• Protein Kinase Inhibitors / adverse effects
• Protein Kinase Inhibitors / pharmacokinetics
• Protein Kinase Inhibitors / therapeutic use
• Pyrimidines / administration & dosage*
• Pyrimidines / adverse effects
• Pyrimidines / pharmacokinetics
• Pyrimidines / therapeutic use
• Remission Induction
• Retrospective Studies
• Thrombocytopenia / chemically induced